Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
adenosine deaminase activity (ADA) has been reported to be elevated in various diseases such as psoriasis, acne and juvenile idiopathic arthritis. There is no previous studies that assessed ADA in chronic spontaneous urticaria (CSU) .
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CSU group | Adult patients complaining of chronic spontaneous urticaria (CSU) |
| |
| Control group | A group of age and sex-matched healthy controls (blood donors). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Adenosine deaminase serum level | Diagnostic Test | Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA). |
| Measure | Description | Time Frame |
|---|---|---|
| Serum level of adenosine deaminase | Difference in serum level of adenosine deaminase between CSU group and control group | 3 months |
| Serum level of IgE | Difference in serum level of IgE between CSU group and control group | 3 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Settings: Dermatology outpatient clinics and Central Research Lab at Sohag University.
Study population: The study will include adult patients complaining of CSU and a group of age and sex-matched healthy controls (blood donors).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed M Ahmed, M.B.B.Ch | Contact | +201093593974 | Dr.ahmed.elsheikh94@gmail.com | |
| Ramadan Saleh, MD | Contact | +201005423054 | salehr2010@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Ramadan Saleh, MD | Sohag University | Study Director |
Not provided
IPD will be shared upon request to the study director
Data will become available after study due for unlimited period of time.
IPD will be shared upon request by the study director. Patients' names will be anonymous.
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 14, 2026 | |
| Reset | Jun 9, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 14, 2026 | Jun 9, 2026 |
| ID | Term |
|---|---|
| D000080223 | Chronic Urticaria |
| ID | Term |
|---|---|
| D014581 | Urticaria |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| IgE antibodies serum level | Diagnostic Test | Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA). |
|
| D006969 |
| Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |